Matsumoto M; Takayama R; Matsuguchi C; Shimada H; Izumi T; Kato N; Matsuo-Tani A; Nakamura H; Hiu T; Matsuo T; Mukai H; Kawakami S · 2026 · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Paper
Lipid nanoparticles (LNPs) have emerged as a key delivery platform for mRNA therapeutics, as demonstrated by the clinical success of mRNA vaccines against SARS-CoV-2. LNPs are now being investigated for various applications, such as cancer immunotherapy and the treatment of genetic disorders. However, LNPs tend to accumulate predominantly in the liver and lack intrinsic cell-type specificity. Modifying LNPs with antibodies is a promising strategy for enhancing cell-specific delivery. We have previously developed orientation-controlled anti-transferrin receptor and anti-PD-L1 antibody modifications for the targeted delivery of nucleic acids, including mRNA and siRNA. In this study, we newly applied this platform to trastuzumab, a clinically established high-affinity anti-HER2 therapeutic antibody, to develop orientation-controlled trastuzumab-modified mRNA/LNPs for HER2-selective delivery. we evaluated trastuzumab-modified mRNA/LNPs in HER2-overexpressing SKOV-3 ovarian cancer cells and HER2-low MDA-MB-231 breast cancer cells. Trastuzumab-modified mRNA/LNPs exhibited over 100-fold greater cellular association than unmodified LNPs in cultured HER2-overexpressing SKOV-3 cells. Furthermore, after intratumoral administration in a mouse model bearing subcutaneous SKOV-3 tumors, the trastuzumab-modified group showed significantly higher luciferase expression than the unmodified and isotype-controlled antibody-modified groups. These findings support FcBP-HFQ lipid-mediated trastuzumab modification of LNPs as a useful approach for efficient cell-selective mRNA delivery.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Almohanad A. Alkayyal
Wells CR; Pandey A; Bawden C; Ye Y; Bilori B; Potter-Schwartz L; Ayaz L; Moghadas SM; Townsend JP; Fitzpatrick MC; Galvani AP
Din MU; Ahmad S; Liu X; Jiang H; Wang X
Li T; Shi Y; Xu HJ; Zhang YB; Wang ZY; Lu LH
da Veiga GTS; de Lima JD; Albrecht L
Pineda JE; Minowa T; Shen L; Zhou Y; Dyevoich A; Patel B; Schneider SM; Keshari S; Saha A; Riba MN; Wang J; Watowich SS; Gubin MM
Source record